Monoclonal antibodies remain effective against latest SARS-CoV-2 variants
Monoclonal antibody therapies continue to neutralise SARS-CoV-2 variants currently in circulation, including Omicron BA.4/5, according to laboratory findings from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, published as a research letter in The Lancet.
Published: 6 October 2022